Spatiotemporal heterogeneity characterizes the genetic landscape of pheochromocytoma and defines early events in tumorigenesis

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4451-4460

  Crona, Joakim ^a   Backman, Samuel ^a   Maharjan, Rajani ^a   Mayrhofer, Markus ^a   Stålberg, Peter ^a   Isaksson, Anders ^a   Hellman, Per ^a   Björklund, Peyman ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MAX PROTEIN; PROTEIN RET; VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 11P; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME LOSS; CONTROLLED STUDY; COPY NUMBER VARIATION; EPAS1 GENE; FEMALE; GENE; GENE SEQUENCE; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAX GENE; NF1 GENE; ONCOGENE H RAS; PHEOCHROMOCYTOMA; PHYLOGENETIC TREE; PRIORITY JOURNAL; RET GENE; SDHAF2 GENE; SDHB GENE; SDHC GENE; SDHD GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TMEM127 GENE; VHL GENE; CANCER STAGING; CELL TRANSFORMATION; CLONAL EVOLUTION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; GENOMIC INSTABILITY; HIGH THROUGHPUT SEQUENCING; METASTASIS; MUTATION; PATHOLOGY; PHYLOGENY; PLOIDY;

CELL TRANSFORMATION, NEOPLASTIC; CLONAL EVOLUTION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PHEOCHROMOCYTOMA; PHYLOGENY; PLOIDIES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84945567521     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2854     Document Type: Article

References (45)

1. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014;14:108-19.
2. Manger WM, Gifford RW Jr., Hoffman BB. Pheochromocytoma: a clinical and experimental overview. Curr Probl Cancer 1985;9:1-89.
3. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915-42.
4. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011;20:3974-85.
5. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. AHIF1alpha regulatory loop links hypoxia andmitochondrial signals in pheochromocytomas. PLoS Genet 2005;1:72-80.
6. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004;11:897-911.
7. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011;18:97-111.
8. Welander J, Soderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011;18:R253-76.
9. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013;21:00183-9.
10. Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun 2015;6:6044.
11. Kugelberg J, Welander J, Schiavi F, Fassina A, Backdahl M, Larsson C, et al. Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas. World J Surg 2014;38:724-32.
12. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 2000;85: 4568-74.
13. Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I, Loriot C, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012;6:6.
14. Comino-Mendez I, de Cubas AA, Bernal C, Alvarez-Escola C, Sanchez-Malo C, Ramirez-Tortosa CL, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 2013;26:26.
15. Welander J, Larsson C, Backdahl M, Hareni N, Sivler T, Brauckhoff M, et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 2012;24:24.
16. Sandgren J, Diaz de Stahl T, Andersson R, Menzel U, Piotrowski A, Nord H, et al. Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis. Endocr Relat Cancer 2010;17: 561-79.
17. Petri BJ, Speel EJ, Korpershoek E, Claessen SM, van Nederveen FH, Giesen V, et al. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod Pathol 2008;21:407-13.
18. August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, et al. CGHand CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 2004;17:1119-28.
19. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46: 225-33.
20. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
21. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-60.
22. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell 2012;149:994-1007.
23. Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
24. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014;25:91-101.
25. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol 2014;12:e1001906.
26. Crona J, Nordling M, Maharjan R, Granberg D, Stalberg P, Hellman P, et al. Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours. PLoS One 2014;9: e86756.
27. Crona J, Maharjan R, Delgado Verdugo A, Stålberg P, Granberg D, Hellman P, et al. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours. Fam Cancer 2013;7:7.
28. Crona J, Delgado Verdugo A, Maharjan R, Stalberg P, Granberg D, Hellman P, et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 2013;98:E1266-71.
29. Crona J, Delgado Verdugo A, Granberg D, Welin S, Stålberg P, Hellman P, et al. Next generation sequencing in genetic screening of pheochromocytoma and paraganglioma. Endocr Connect 2013;2:104-11.
30. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107:16910-5.
31. Rasmussen M, Sundstrom M, Goransson Kultima H, Botling J, Micke P, Birgisson H, et al. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol 2011;12:R108.
32. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013;30:2725-9.
33. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014;46:607-12.
34. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413-21.
35. Gusnanto A, Wood HM, Pawitan Y, Rabbitts P, Berri S. Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data. Bioinformatics 2012;28:40-7.
36. Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, Garcia F, et al. Highresolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 2006;16:1136-48.
37. Ke R, Mignardi M, Pacureanu A, Svedlund J, Botling J, Wahlby C, et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods 2013;10:857-60.
38. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013;110:4009-14.
39. Korpershoek E, Stobbe CK, van Nederveen FH, de Krijger RR, Dinjens WN. Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas. Endocr Relat Cancer 2010;17:653-62.
40. Blanes A, Sanchez-Carrillo JJ, Diaz-Cano SJ. Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair. J Clin Endocrinol Metab 2006;91:1150-8.
41. Dannenberg H, Komminoth P, Dinjens WN, Speel EJ, de Krijger RR. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr Pathol 2003;14:329-50.
42. Conway Morris S. Life's Solution: inevitable humans in a lonely universe: New York: Cambridge University Press; 2003.
43. Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, et al. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol 2014;15:433.
44. Flynn A, Benn D, Clifton-Bligh R, Robinson B, Trainer AH, James P, et al. The genomic landscape of phaeochromocytoma. J Pathol 2015;236:78-89.
45. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, et al. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 2002;13:17-27.